Human Clinical Trial Begins For Texas A&M-Discovered Drug To Treat Angelman Syndrome
Developed by biopharmaceutical company Ultragenyx, GTX-102 is the first clinically developed drug targeting the genetic causes of Angelman syndrome rather than symptoms.